- <![CDATA[FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma ]]><![CDATA[The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma. ]]>onclive · 2mo ago↗ source
- <![CDATA[GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026]]><![CDATA[We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.]]>onclive · 2mo ago↗ source
- Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion<figure><div><img src="https://imgproxy.divecdn.com/d3kyAOKiV4alroZs496u4_W_RA0u2QbwRQbzfwY4ALY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNjg5NTg1NDg3X3JmN…